|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: WBP4 |
Gene summary for WBP4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | WBP4 | Gene ID | 11193 |
| Gene name | WW domain binding protein 4 | |
| Gene Alias | FBP21 | |
| Cytomap | 13q14.11 | |
| Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | O75554 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 11193 | WBP4 | LZE4T | Human | Esophagus | ESCC | 5.82e-04 | 2.10e-01 | 0.0811 |
| 11193 | WBP4 | LZE7T | Human | Esophagus | ESCC | 1.35e-08 | 3.45e-01 | 0.0667 |
| 11193 | WBP4 | LZE20T | Human | Esophagus | ESCC | 2.45e-02 | 1.23e-01 | 0.0662 |
| 11193 | WBP4 | LZE24T | Human | Esophagus | ESCC | 1.20e-11 | 2.80e-01 | 0.0596 |
| 11193 | WBP4 | P1T-E | Human | Esophagus | ESCC | 6.09e-08 | 4.24e-01 | 0.0875 |
| 11193 | WBP4 | P2T-E | Human | Esophagus | ESCC | 1.89e-26 | 5.74e-01 | 0.1177 |
| 11193 | WBP4 | P4T-E | Human | Esophagus | ESCC | 1.61e-23 | 6.38e-01 | 0.1323 |
| 11193 | WBP4 | P5T-E | Human | Esophagus | ESCC | 5.13e-16 | 1.47e-01 | 0.1327 |
| 11193 | WBP4 | P8T-E | Human | Esophagus | ESCC | 4.39e-30 | 6.69e-01 | 0.0889 |
| 11193 | WBP4 | P9T-E | Human | Esophagus | ESCC | 4.24e-23 | 5.43e-01 | 0.1131 |
| 11193 | WBP4 | P10T-E | Human | Esophagus | ESCC | 2.56e-35 | 6.23e-01 | 0.116 |
| 11193 | WBP4 | P11T-E | Human | Esophagus | ESCC | 8.03e-05 | 2.98e-01 | 0.1426 |
| 11193 | WBP4 | P12T-E | Human | Esophagus | ESCC | 1.11e-26 | 2.47e-01 | 0.1122 |
| 11193 | WBP4 | P15T-E | Human | Esophagus | ESCC | 1.08e-19 | 5.12e-01 | 0.1149 |
| 11193 | WBP4 | P16T-E | Human | Esophagus | ESCC | 5.88e-25 | 3.49e-01 | 0.1153 |
| 11193 | WBP4 | P17T-E | Human | Esophagus | ESCC | 2.06e-09 | 4.18e-01 | 0.1278 |
| 11193 | WBP4 | P19T-E | Human | Esophagus | ESCC | 2.46e-10 | 4.55e-01 | 0.1662 |
| 11193 | WBP4 | P20T-E | Human | Esophagus | ESCC | 4.88e-10 | 3.05e-01 | 0.1124 |
| 11193 | WBP4 | P21T-E | Human | Esophagus | ESCC | 7.69e-23 | 3.59e-01 | 0.1617 |
| 11193 | WBP4 | P22T-E | Human | Esophagus | ESCC | 5.35e-18 | 2.59e-01 | 0.1236 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0008380111 | Esophagus | ESCC | RNA splicing | 336/8552 | 434/18723 | 1.74e-42 | 3.67e-39 | 336 |
| GO:0000375111 | Esophagus | ESCC | RNA splicing, via transesterification reactions | 248/8552 | 324/18723 | 3.05e-30 | 1.49e-27 | 248 |
| GO:0000377111 | Esophagus | ESCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
| GO:0000398111 | Esophagus | ESCC | mRNA splicing, via spliceosome | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
| GO:000838012 | Liver | Cirrhotic | RNA splicing | 229/4634 | 434/18723 | 9.13e-37 | 2.86e-33 | 229 |
| GO:000037512 | Liver | Cirrhotic | RNA splicing, via transesterification reactions | 175/4634 | 324/18723 | 5.95e-30 | 7.47e-27 | 175 |
| GO:000037712 | Liver | Cirrhotic | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 172/4634 | 320/18723 | 4.02e-29 | 3.60e-26 | 172 |
| GO:000039812 | Liver | Cirrhotic | mRNA splicing, via spliceosome | 172/4634 | 320/18723 | 4.02e-29 | 3.60e-26 | 172 |
| GO:000838022 | Liver | HCC | RNA splicing | 313/7958 | 434/18723 | 1.36e-36 | 1.73e-33 | 313 |
| GO:000037522 | Liver | HCC | RNA splicing, via transesterification reactions | 228/7958 | 324/18723 | 1.47e-24 | 4.06e-22 | 228 |
| GO:000037722 | Liver | HCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 224/7958 | 320/18723 | 1.16e-23 | 2.62e-21 | 224 |
| GO:000039822 | Liver | HCC | mRNA splicing, via spliceosome | 224/7958 | 320/18723 | 1.16e-23 | 2.62e-21 | 224 |
| GO:000838020 | Oral cavity | OSCC | RNA splicing | 308/7305 | 434/18723 | 2.43e-42 | 7.70e-39 | 308 |
| GO:000037519 | Oral cavity | OSCC | RNA splicing, via transesterification reactions | 225/7305 | 324/18723 | 5.20e-29 | 2.99e-26 | 225 |
| GO:000037719 | Oral cavity | OSCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 221/7305 | 320/18723 | 5.50e-28 | 2.18e-25 | 221 |
| GO:000039819 | Oral cavity | OSCC | mRNA splicing, via spliceosome | 221/7305 | 320/18723 | 5.50e-28 | 2.18e-25 | 221 |
| GO:0008380110 | Oral cavity | LP | RNA splicing | 237/4623 | 434/18723 | 1.82e-41 | 3.79e-38 | 237 |
| GO:0000375110 | Oral cavity | LP | RNA splicing, via transesterification reactions | 181/4623 | 324/18723 | 1.36e-33 | 1.70e-30 | 181 |
| GO:0000377110 | Oral cavity | LP | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 179/4623 | 320/18723 | 2.48e-33 | 2.22e-30 | 179 |
| GO:0000398110 | Oral cavity | LP | mRNA splicing, via spliceosome | 179/4623 | 320/18723 | 2.48e-33 | 2.22e-30 | 179 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| WBP4 | SNV | Missense_Mutation | novel | c.1031N>A | p.Ser344Tyr | p.S344Y | O75554 | protein_coding | deleterious(0) | possibly_damaging(0.651) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| WBP4 | SNV | Missense_Mutation | c.234N>T | p.Glu78Asp | p.E78D | O75554 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-C8-A12M-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| WBP4 | SNV | Missense_Mutation | novel | c.928N>T | p.Val310Leu | p.V310L | O75554 | protein_coding | deleterious(0) | benign(0.053) | TCGA-C5-A902-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| WBP4 | SNV | Missense_Mutation | novel | c.576G>T | p.Glu192Asp | p.E192D | O75554 | protein_coding | deleterious(0.02) | probably_damaging(0.96) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| WBP4 | SNV | Missense_Mutation | c.1052G>T | p.Gly351Val | p.G351V | O75554 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| WBP4 | SNV | Missense_Mutation | c.1046C>T | p.Ala349Val | p.A349V | O75554 | protein_coding | deleterious(0.02) | benign(0.158) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
| WBP4 | SNV | Missense_Mutation | c.788N>C | p.Asp263Ala | p.D263A | O75554 | protein_coding | tolerated(0.6) | benign(0) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| WBP4 | SNV | Missense_Mutation | novel | c.365N>C | p.Asp122Ala | p.D122A | O75554 | protein_coding | tolerated(0.4) | benign(0.162) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| WBP4 | SNV | Missense_Mutation | rs760308349 | c.854C>T | p.Ser285Leu | p.S285L | O75554 | protein_coding | tolerated(0.13) | benign(0.143) | TCGA-AA-3939-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| WBP4 | SNV | Missense_Mutation | c.199N>T | p.Ala67Ser | p.A67S | O75554 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-AZ-4308-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Targeted Molecular therapy | avastin | CR |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |